NCT03758456View on ClinicalTrials.gov

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

May 17, 2019

Study Completion Date

May 17, 2019

Conditions
Rhinitis, AllergicRhinoconjunctivitis, Allergic
Interventions
BIOLOGICAL

HAL-MRE1

HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.

Trial Locations (1)

ON L4W 1A4

Inflamax Research Inc., Mississauga

Sponsors

Lead Sponsor

HAL Allergy
All Listed Sponsors
lead

HAL Allergy

INDUSTRY

NCT03758456 - HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human | Biotech Hunter | Biotech Hunter